FAQ
::
Szukaj
::
Użytkownicy
::
Grupy
::
Galerie
::
Profil
::
Zaloguj się, by sprawdzić wiadomości
::
Zaloguj
::
Rejestracja
Forum Stowarzyszenie "Rowling" Strona Główna
->
Reklamy
Napisz odpowiedź
Użytkownik
Temat
Treść wiadomości
Emotikony
Więcej Ikon
Kolor:
Domyślny
Ciemnoczerwony
Czerwony
Pomarańćzowy
Brązowy
Żółty
Zielony
Oliwkowy
Błękitny
Niebieski
Ciemnoniebieski
Purpurowy
Fioletowy
Biały
Czarny
Rozmiar:
Minimalny
Mały
Normalny
Duży
Ogromny
Zamknij Tagi
Opcje
HTML:
TAK
BBCode
:
TAK
Uśmieszki:
TAK
Wyłącz HTML w tym poście
Wyłącz BBCode w tym poście
Wyłącz Uśmieszki w tym poście
Kod potwierdzający: *
Wszystkie czasy w strefie CET (Europa)
Skocz do:
Wybierz forum
Administracja
----------------
Tematyka forum
Ważne
Użytkownicy
----------------
Coś o nas
Nasza twórczość
Galeria
Rowling
----------------
Książki
Filmy
Serie, opowiadania
Inne
Inne
----------------
Kultura
Hyde park
Reklamy
Shoutbox
----------------
kilka informacji o shoutboxie
Przegląd tematu
Autor
Wiadomość
43c47jgn31jh
Wysłany: Pią 8:08, 11 Lut 2011
Temat postu: WuXi PharmaTech Well Positioned to Continue Growin
WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that its previously announced transaction with Charles River Laboratories International Inc. (NYSE: CRL) has been terminated by mutual agreement due to Charles River shareholder opposition. Under the terms of the termination agreement, WuXi will receive a breakup fee of $30 million.
"WuXi‘s strategy has not changed. Our goal is, and has long been, to build a broad,
Business process outsourcing
, integrated R&D service platform designed to help our customers improve the success of research and shorten the time of new product development,
hospitality solution
," said Dr. Ge Li, Chairman and Chief Executive Officer. "While we are disappointed that this transaction could not be completed,
Mobile solution
, WuXi remains well positioned to meet our customers‘ needs and to continue to grow and expand as a standalone company.
"All of our businesses are performing very well," Dr. Li continued. "Each business unit has met or exceeded its targets for the second quarter, and we recently increased our guidance for full-year 2010 financial performance.
"Virtually all of the large global pharmaceutical companies, as well as hundreds of smaller pharmaceutical and biotech companies and many leading medical device companies,
Help desk outsourcing
, are our customers," Dr. Li concluded. "We believe that strong trends for greater outsourcing and offshoring of R&D services will continue, and that WuXi, as the leading China-based contract research organization, is well positioned to benefit from this powerful outsourcing trend for many years to come."
Second Quarter Results
WuXi will report financial results for the second quarter ending June 30,
health care outsourcing
, 2010, on Monday, August 2, at 6:30 am EDT with a conference call at 8:30 am EDT to discuss the results and the outlook for WuXi‘s business. The conference call may be accessed by calling:
United States: 1-866-519-4004
China (Landline): 800-819-0121
China (Mobile): 400-620-8038
Hong Kong: 800-930-346
United Kingdom: 0-808-234-6646
International: +65-6723-9381
Conference ID: 90840146
Web PIN: 8656
A replay will be available two hours after the call‘s completion at:
United States: 1-866-214-5335
China North: 10-800-714-0386
China South: 10-800-140-0386
Hong Kong: 800-901-596
United Kingdom: 0-800-731-7846
International: +61-2-8235-5000
Passcode: 90840146
A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech‘s website at .
fora.pl
- załóż własne forum dyskusyjne za darmo
Powered by
phpBB
(C) 2001, 2005 phpBB Group
Theme Retred created by
JR9
for
stylerbb.net
Bearshare
Regulamin